Astrocytoma

P1, N=12, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting

P1, N=102, Recruiting, Jazz Pharmaceuticals | Trial primary completion date: Dec 2025 --> Jul 2026

P1, N=18, Recruiting, Henry Ford Health System | Trial completion date: Oct 2026 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Jan 2027

P2, N=10, Not yet recruiting, Institut de Recherches Internationales Servier (I.R.I.S.)

MGMTp methylation was not associated with a prognostic or predictive value in our IDH-mutant glioma cohort. CDKN2A/B status and extent of resection were strong predictors of outcomes.

Conventional radiotherapy combined with temozolomide proved ineffective. This is the first reported case of multi-oncogenic pathway alterations following BRAF-targeted therapy in PXA. These genetic abnormalities likely contributed to the tumor's drug resistance and aggressive progression in this case.

Multi-omic integration identified N-glycosylation as the best classifier of grade, while the immune transcriptome best predicted GBM survival. Provided as a community resource, this study offers a framework for glioma targeting, classification, outcome prediction, and a baseline of TME composition across all stages.

The clinical applicability of these tests must be corroborated with clinical presentation and neurosurgical resection to highlight progression and recurrence rates. Standardized protocols and molecular-based evidence are essential for optimizing patient management and outcomes.

Contemporary glioma cohorts showed prolonged survival outcomes compared to historical cohorts. An association between anatomic localization and molecular subtypes was also established in this Chinese glioma cohort.

Overall, the R273C mutation, although mechanistically unclear, is more prevalent than other TP53 variants and defines a distinct biological subset of LGIMAs, marked by increased Ki-67 and female predominance. Incorporating TP53 and broader genetic profiling via NGS could improve our understanding of LGIMAs and support a refined classification system, enhancing diagnostic and prognostic accuracy.

High [18F] Fluciclovine uptake in pilocytic astrocytoma may reflect amino acid transporter expression, which may lead to overestimation of the WHO grade. Awareness of this pitfall is essential in pediatric neuro-oncology.